Anavex Life Sciences Corp.
AVXLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAnavex Life Sciences Corp. operates as a biopharmaceutical company. With a market capitalization of $264.2M, it sits in micro-cap territory. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer.
Market Cap
$264.2M
Beta
1.14
P/E (TTM)
—
P/E (Fwd)
-5.18
EPS (TTM)
$-0.14
EPS (Fwd)
$-0.55
ROE
-12.8%
ROA
-9.7%
Cash
$118.3M
Total Debt
$0
Free CF
-$27.1M
52W Change
-67.8%
Annual Financials
Cash vs Debt
Where AVXL stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, AVXL finished 8.26% below its 150-day moving average ($3.39) and 14.33% below its 200-day moving average ($3.63). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVXL overbought or oversold?
At the August 25, 2026 close, AVXL's RSI(14) was 48.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Anavex Life Sciences Corp. reports $118.3M in cash and $0 in total debt. Free cash flow is running at -$27.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -12.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Anavex Life Sciences Corp. and its sector.